Efeito Cardioprotetor da Melatonina Versus Vitamina D em Pacientes com Cancro da Mama a Receber Doxorrubicina
Estudo Clínico a Avaliar o Efeito Cardioprotetor da Melatonina em Comparação com a Vitamina D em Doentes com Cancro da Mama em Tratamento com Doxorrubicina
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.
Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .
Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .
To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .
Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .
Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .
Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Tanta, Egito
- Tanta University
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age from 18 to 65 years old.
- Gender: female.
- Positive breast cancer women who are scheduled to receive Doxorubicin.
- Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
- Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
- Normal renal and liver function tests.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Women with HER-2 positive of breast cancer.
- Formerly treated with Doxorubicin.
- Patients with a known hypersensitivity to any of the used drugs.
- On other concomitant vitamins or food supplements.
- Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
- Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction < 50%.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Group 1 (Doxorubicin group)
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks. |
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks. |
|
Experimental: Group 2 (Vitamin D group)
patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks |
patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks |
|
Experimental: Group 3 (melatonin group)
30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks. |
patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Decreasing incidence and severity of cardiotoxicity
Prazo: 12 weeks
|
Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment. |
12 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Plasma B-Type Natriuretic Peptide (BNP) Concentration
Prazo: Baseline and 12 weeks.
|
Change in plasma B-type natriuretic peptide (BNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL. |
Baseline and 12 weeks.
|
|
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Prazo: Baseline and 12 weeks.
|
Change in serum/plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL. |
Baseline and 12 weeks.
|
|
Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Concentration
Prazo: Baseline and 12 weeks.
|
Change in serum/plasma high-sensitivity cardiac troponin I (hs-cTnI) concentration from baseline to 12 weeks, measured using the Alinity i STAT High Sensitive Troponin-I chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L. |
Baseline and 12 weeks.
|
|
Change in Myeloperoxidase (MPO) Concentration
Prazo: Baseline and 12 weeks.
|
Change in myeloperoxidase (MPO) concentration from baseline to 12 weeks, measured using a human MPO double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL. |
Baseline and 12 weeks.
|
|
Change in Interleukin-6 (IL-6) Concentration
Prazo: Baseline and 12 weeks.
|
Change in interleukin-6 (IL-6) concentration from baseline to 12 weeks, measured using a human IL-6 double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L. |
Baseline and 12 weeks.
|
|
Change in Creatine Kinase-MB (CK-MB) Concentration
Prazo: Baseline and 12 weeks.
|
Change in serum/plasma creatine kinase-MB (CK-MB) concentration from baseline to 12 weeks, measured using the Alinity i STAT CK-MB chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL. |
Baseline and 12 weeks.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
Outros números de identificação do estudo
- 36265MD408/5/25
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
All data will be available when needed
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .